New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen

CompletedOBSERVATIONAL

Enrollment

136

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

January 30, 2024

Study Completion Date

July 30, 2024

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG

Orelabrutinib

Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d

Trial Locations (1)

Department of Hematology, Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Huashan Hospital

OTHER